No takes yet. Share an insight, caveat, or question.
Systematic review evaluates treatment efficacy for chronic graft-versus-host disease, revealing ruxolitinib as effective.
Zhou et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: